View ValuationArcher Materials 将来の成長Future 基準チェック /06現在、 Archer Materialsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Semiconductor 収益成長25.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Sep 19Archer Materials Limited, Annual General Meeting, Nov 20, 2025Archer Materials Limited, Annual General Meeting, Nov 20, 2025.お知らせ • May 05+ 1 more updateArcher Materials Limited Announces Resignation of Damien Connor, Chief Financial Officer, Effective 30 June 2025Archer Materials Limited announced Mr. Damien Connor, the Company's Chief Financial Officer has provided notice of resignation to the Company. Mr. Connor has agreed to assist as required to ensure a smooth transition through to 30 June 2025.お知らせ • Oct 18Archer Materials Limited, Annual General Meeting, Nov 20, 2024Archer Materials Limited, Annual General Meeting, Nov 20, 2024. Location: stone & chalk sydney scaleup hub, level 2, 477 pitt street, haymarket, 2000., Australiaお知らせ • Jul 13Mohammad Choucair to Step Down as Chief Executive Officer of Archer Materials Limited in January 2025Archer Materials Limited announced the departure of Dr. Mohammad Choucair as Chief Executive Officer ("CEO"). Mohammad will step down from the CEO role in January 2025 to ensure a smooth transition and handover. Mohammad retires from the Company for personal reasons.お知らせ • Mar 15Archer Materials Limited Designs Miniaturised Version of Biochip Biochip Graphene Field Effect Transistor ChipArcher Materials Limited has designed a miniaturised version of its Biochip graphene field effect transistor (“gFET”) chip for fabrication at a commercial foundry. The Archer Biochip contains a sensing region of which the gFET is the core component. Each gFET chip contains multiple gFETs, each of which is a transistor, which acts as a sensor. Archer has miniaturised the total chip size by redesigning the layout of the circuits creating these gFET transistors. The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology. The new gFET chip design has been significantly reduced in size over earlier designs of 10mm x 10mm to 1.5mm x 1.5mm. It will be tested on a four-inch wafer which is expected to produce 1375 chips on it, compared to the 45 chips produced using earlier designs in previous four-inch wafer fabrication runs. The chip will be fabricated by Applied Nanolayers (“ANL”), based in the Netherlands, which has fabricated earlier designs of Archer’s gFETs (ASX ann. 14 September 2023). Independent to wafer runs at ANL, Archer has also sent gFET designs to a foundry in Spain for fabrication, with delivery anticipated within the first half of 2024 (ASX ann. 11 December 2023). Archer applies the ‘fabless’ chipmaker model by designing, researching, and developing its chips, while outsourcing manufacturing to specialised companies in the semiconductor supply chain. This includes the creation of a new miniaturised Biochip gFET chip design, sending the design for a whole wafer run in a commercial foundry, and deciding on the chip assembly and semiconductor device electronics packaging and related electrical testing. The wafer will be diced and assembled at Archer’s newly established outsourced semiconductor assembly and testing (“OSAT”) partner, AOI Electronics in Japan. The OSAT includes moulding, dicing, and lead frame design for this dedicated wafer assembly, and also device electronic shorting and related packaging testing. These new capabilities are key in advancing the Biochip development to interfacing and integration with miniaturised gFET chip sensor designs. Delivery of the packaged chips is anticipated in mid-2024.お知らせ • Nov 02Archer Materials Limited Demonstrates Multiplexing Readout for its Advanced Biochip Graphene Field Effect Transistor DeviceArcher Materials Limited has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (gFET) device. Archer confirmed single-device multiplexing using four advanced gFETs as sensors, which were integrated into the Archer advanced Biochip platform that was announced on 14 September 2023. This is significant as Archer intends to apply its multiplexing capability in the Biochip to test for multiple diseases on a single chip at once. Archer designed and developed the new hardware and software systems to readout the signal from the four advanced gFET sensors at once on a single chip. This is a significant advance over the earlier generation of the Biochip system, which could only activate one-sensor-at-a-time. The new Biochip system with multiplexing capability also provides automated hands-free operation, as it integrates liquid handling automation and data acquisition. The software developed by Archer can display all single and time series measurements in real-time for the four gFET sensors simultaneously.お知らせ • Oct 28Archer Materials Limited, Annual General Meeting, Nov 29, 2023Archer Materials Limited, Annual General Meeting, Nov 29, 2023, at 10:30 E. Australia Standard Time. Location: KPMG, Level 38, Tower Three, International Towers Sydney 300 Barangaroo Avenue Sydney New South Wales Australia Agenda: To consider he Remuneration Report for the year ended 30 June 2023; to consider Re-election of Bernadette Harkin as a Director; to consider Approval of Issues of Securities under the New Performance Rights Plan and Share Option Plan; to consider Modification of the Company's Constitution; to consider Approval of 10% additional placement capacity; to consider Renewal of proportional takeover provisions in the Constitution; and to consider other matters.お知らせ • Aug 01Archer Materials Limited Further Enhances Biochip gFET Design for Advanced Sensing and Send to Commercial Foundry PartnerArcher Materials Limited has developed a next generation biochip fabrication to better detect and control disease samples on a single graphene field effect transistor ("gFET") design. The gFET design also has functional surfaces and components, for both the sensor and control of the biochip platform. There is also an integration of gFET design components that allow for the real-time fine tuning and control of the electronic properties of the graphene. This has the potential advantage of biosensors that are re-usable, leading to an extended device lifetime. In addition, Archer has improved its biochip system platform testing capabilities to develop a more accurate sensor. The upgraded automated testing platform conducts both control software and readout hardware with improved efficiency. The software is also progressing towards automated data analysis, so end users can extract high quality data. This new more complex gFET design complements the proof-of-concept biosensing gFET announced on 13 July 2023. The earlier design was submitted to a commercial foundry for a Multi-Project Wafer run, with the completed devices expected to be delivered by the end of 2023. The new advanced device designs which are the subject of this announcement have now been submitted to a foundry in the Netherlands for a whole wafer run (the previous 'simpler' design was submitted to a foundry in Germany for a Multi- Project Wafer ("MPW") run). An MPW is where Archer's device design is imprinted on a small area of a wafer with the designs of other companies on the same wafer. The new more complex gFet design will be fabricated all over one, stand-alone four-inch wafer. The new advanced gFET device design and whole wafer run in a commercial foundry is an example of how Archer is now moving towards a streamlined commercialization model that closely aligns to the 'fabless' model (i.e. Archer focuses on designing and developing its chips and outsources the manufacturing to specialized foundries). The new gFET device designs and related processes form the basis of intellectual property that is 100% owned by Archer.お知らせ • Jul 14Archer Materials Limited Transfers Biochip Graphene Sensor Technology Design to A Commercial Fab to Verify ScalabilityArcher Materials Limited has completed a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. The Archer-designed gFET sensing chips will be produced by a commercial foundry, with the aim of Archer validating its design to ensure appropriate scalability for the manufacturing process. Archer expects completed runs to arrive at the end of 2023. The runs will be evaluated to test which foundry and process are best suited to Archer's technology. Archer's design and process can then be scaled to manufacture complete wafers containing the graphene-based sensors for biochip integration in collaboration with a range of different commercial foundries. Archer has, in parallel, started discussions with potential global foundry partners for initial small production runs of its graphene chip designs to evaluate the reliability of the product. The latest development follows the recent announcement on 10 March 2023 in which the Company gained electronic control of the sensitivity of its incorporated gFET devices so it can better target biomolecules. This followed Archer's early-stage biochip prototype with an integrated system platform for biosensing announced to the market on 16 November 2022, after having developed a 'wettable' gFET announced on 24 October 2022. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Archer Materials は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ARRX.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-6-7-6N/A9/30/20252-6-5-5N/A6/30/20252-7-4-4N/A3/31/20252-7-4-4N/A12/31/20242-6-5-4N/A9/30/20242-6-5-5N/A6/30/20242-5-5-5N/A3/31/20242-7-4-4N/A12/31/20232-8-3-3N/A9/30/20232-9-3-3N/A6/30/20231-9-3-3N/A3/31/20231-12-4-4N/A12/31/20221-14-5-5N/A9/30/20221-14-5-5N/A6/30/20221-14-4-4N/A3/31/20221-9-4-4N/A12/31/20210-5-3-3N/A9/30/20210-4-3-3N/A6/30/20210-3-3-3N/A12/31/20201-2-1-2N/A9/30/20201-2-1-1N/A6/30/20200-3-1-1N/A3/31/20200-3-3-1N/A12/31/20190-2-3-1N/A9/30/20190-2N/A-2N/A6/30/20190-2N/A-2N/A3/31/20190-2N/A-2N/A12/31/20180-2N/A-1N/A9/30/20180-2N/A-1N/A6/30/20180-2N/A-1N/A12/31/20170-1N/A-1N/A9/30/20170-1N/A-1N/A6/30/20170-1N/A-1N/A3/31/20170-1N/A-1N/A12/31/20160-2N/A-1N/A9/30/20160-2N/A-1N/A6/30/20160-1N/A-1N/A3/31/20160-1N/A0N/A12/31/20150-1N/A0N/A9/30/20150-1N/A0N/A6/30/20150-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ARRX.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ARRX.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ARRX.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ARRX.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ARRX.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ARRX.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSemiconductors 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:24終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Archer Materials Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 19Archer Materials Limited, Annual General Meeting, Nov 20, 2025Archer Materials Limited, Annual General Meeting, Nov 20, 2025.
お知らせ • May 05+ 1 more updateArcher Materials Limited Announces Resignation of Damien Connor, Chief Financial Officer, Effective 30 June 2025Archer Materials Limited announced Mr. Damien Connor, the Company's Chief Financial Officer has provided notice of resignation to the Company. Mr. Connor has agreed to assist as required to ensure a smooth transition through to 30 June 2025.
お知らせ • Oct 18Archer Materials Limited, Annual General Meeting, Nov 20, 2024Archer Materials Limited, Annual General Meeting, Nov 20, 2024. Location: stone & chalk sydney scaleup hub, level 2, 477 pitt street, haymarket, 2000., Australia
お知らせ • Jul 13Mohammad Choucair to Step Down as Chief Executive Officer of Archer Materials Limited in January 2025Archer Materials Limited announced the departure of Dr. Mohammad Choucair as Chief Executive Officer ("CEO"). Mohammad will step down from the CEO role in January 2025 to ensure a smooth transition and handover. Mohammad retires from the Company for personal reasons.
お知らせ • Mar 15Archer Materials Limited Designs Miniaturised Version of Biochip Biochip Graphene Field Effect Transistor ChipArcher Materials Limited has designed a miniaturised version of its Biochip graphene field effect transistor (“gFET”) chip for fabrication at a commercial foundry. The Archer Biochip contains a sensing region of which the gFET is the core component. Each gFET chip contains multiple gFETs, each of which is a transistor, which acts as a sensor. Archer has miniaturised the total chip size by redesigning the layout of the circuits creating these gFET transistors. The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology. The new gFET chip design has been significantly reduced in size over earlier designs of 10mm x 10mm to 1.5mm x 1.5mm. It will be tested on a four-inch wafer which is expected to produce 1375 chips on it, compared to the 45 chips produced using earlier designs in previous four-inch wafer fabrication runs. The chip will be fabricated by Applied Nanolayers (“ANL”), based in the Netherlands, which has fabricated earlier designs of Archer’s gFETs (ASX ann. 14 September 2023). Independent to wafer runs at ANL, Archer has also sent gFET designs to a foundry in Spain for fabrication, with delivery anticipated within the first half of 2024 (ASX ann. 11 December 2023). Archer applies the ‘fabless’ chipmaker model by designing, researching, and developing its chips, while outsourcing manufacturing to specialised companies in the semiconductor supply chain. This includes the creation of a new miniaturised Biochip gFET chip design, sending the design for a whole wafer run in a commercial foundry, and deciding on the chip assembly and semiconductor device electronics packaging and related electrical testing. The wafer will be diced and assembled at Archer’s newly established outsourced semiconductor assembly and testing (“OSAT”) partner, AOI Electronics in Japan. The OSAT includes moulding, dicing, and lead frame design for this dedicated wafer assembly, and also device electronic shorting and related packaging testing. These new capabilities are key in advancing the Biochip development to interfacing and integration with miniaturised gFET chip sensor designs. Delivery of the packaged chips is anticipated in mid-2024.
お知らせ • Nov 02Archer Materials Limited Demonstrates Multiplexing Readout for its Advanced Biochip Graphene Field Effect Transistor DeviceArcher Materials Limited has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (gFET) device. Archer confirmed single-device multiplexing using four advanced gFETs as sensors, which were integrated into the Archer advanced Biochip platform that was announced on 14 September 2023. This is significant as Archer intends to apply its multiplexing capability in the Biochip to test for multiple diseases on a single chip at once. Archer designed and developed the new hardware and software systems to readout the signal from the four advanced gFET sensors at once on a single chip. This is a significant advance over the earlier generation of the Biochip system, which could only activate one-sensor-at-a-time. The new Biochip system with multiplexing capability also provides automated hands-free operation, as it integrates liquid handling automation and data acquisition. The software developed by Archer can display all single and time series measurements in real-time for the four gFET sensors simultaneously.
お知らせ • Oct 28Archer Materials Limited, Annual General Meeting, Nov 29, 2023Archer Materials Limited, Annual General Meeting, Nov 29, 2023, at 10:30 E. Australia Standard Time. Location: KPMG, Level 38, Tower Three, International Towers Sydney 300 Barangaroo Avenue Sydney New South Wales Australia Agenda: To consider he Remuneration Report for the year ended 30 June 2023; to consider Re-election of Bernadette Harkin as a Director; to consider Approval of Issues of Securities under the New Performance Rights Plan and Share Option Plan; to consider Modification of the Company's Constitution; to consider Approval of 10% additional placement capacity; to consider Renewal of proportional takeover provisions in the Constitution; and to consider other matters.
お知らせ • Aug 01Archer Materials Limited Further Enhances Biochip gFET Design for Advanced Sensing and Send to Commercial Foundry PartnerArcher Materials Limited has developed a next generation biochip fabrication to better detect and control disease samples on a single graphene field effect transistor ("gFET") design. The gFET design also has functional surfaces and components, for both the sensor and control of the biochip platform. There is also an integration of gFET design components that allow for the real-time fine tuning and control of the electronic properties of the graphene. This has the potential advantage of biosensors that are re-usable, leading to an extended device lifetime. In addition, Archer has improved its biochip system platform testing capabilities to develop a more accurate sensor. The upgraded automated testing platform conducts both control software and readout hardware with improved efficiency. The software is also progressing towards automated data analysis, so end users can extract high quality data. This new more complex gFET design complements the proof-of-concept biosensing gFET announced on 13 July 2023. The earlier design was submitted to a commercial foundry for a Multi-Project Wafer run, with the completed devices expected to be delivered by the end of 2023. The new advanced device designs which are the subject of this announcement have now been submitted to a foundry in the Netherlands for a whole wafer run (the previous 'simpler' design was submitted to a foundry in Germany for a Multi- Project Wafer ("MPW") run). An MPW is where Archer's device design is imprinted on a small area of a wafer with the designs of other companies on the same wafer. The new more complex gFet design will be fabricated all over one, stand-alone four-inch wafer. The new advanced gFET device design and whole wafer run in a commercial foundry is an example of how Archer is now moving towards a streamlined commercialization model that closely aligns to the 'fabless' model (i.e. Archer focuses on designing and developing its chips and outsources the manufacturing to specialized foundries). The new gFET device designs and related processes form the basis of intellectual property that is 100% owned by Archer.
お知らせ • Jul 14Archer Materials Limited Transfers Biochip Graphene Sensor Technology Design to A Commercial Fab to Verify ScalabilityArcher Materials Limited has completed a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. The Archer-designed gFET sensing chips will be produced by a commercial foundry, with the aim of Archer validating its design to ensure appropriate scalability for the manufacturing process. Archer expects completed runs to arrive at the end of 2023. The runs will be evaluated to test which foundry and process are best suited to Archer's technology. Archer's design and process can then be scaled to manufacture complete wafers containing the graphene-based sensors for biochip integration in collaboration with a range of different commercial foundries. Archer has, in parallel, started discussions with potential global foundry partners for initial small production runs of its graphene chip designs to evaluate the reliability of the product. The latest development follows the recent announcement on 10 March 2023 in which the Company gained electronic control of the sensitivity of its incorporated gFET devices so it can better target biomolecules. This followed Archer's early-stage biochip prototype with an integrated system platform for biosensing announced to the market on 16 November 2022, after having developed a 'wettable' gFET announced on 24 October 2022.